Evercore ISI lowered the firm’s price target on Twist Bioscience (TWST) to $46 from $50 and keeps an Outperform rating on the shares. The firm updated the company’s model post the fiscal Q3 report. It views the quarter as “decent” with solid gross margins. Twist has solid momentum entering fiscal 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST: